Metastasis of tumors requires angiogenesis, which is comprised of multiple biological processes that are regulated by angiogenic factors. The fibroblast growth factor (FGF) is a potent angiogenic factor and aberrant FGF signaling is a common property of tumors. Yet, how the aberration in cancer cells contributes to angiogenesis in the tumor is not well understood. Most studies of its angiogenic signaling mechanisms have been in endothelial cells. FGF receptor substrate 2α (FRS2α) is an FGF receptor-associated protein required for activation of downstream signaling molecules that include those in the mitogen-activated protein and AKT kinase pathways. Herein, we demonstrated that overactivation and hyperactivity of FRS2α, as well as overexpression of cJUN and HIF1α, were positively correlated with vessel density and progression of human prostate cancer (PCa) toward malignancy. We also demonstrate that FGF upregulated the production of vascular endothelial growth factor A mainly by increasing expression of cJUN and HIF1α. This then promoted recruitment of endothelial cells and vessel formation for the tumor. Tumor angiogenesis in mouse PCa tissues was compromised by tissue-specific ablation of Frs2α in prostate epithelial cells. Depletion of Frs2α expression in human PCa cells and in a preclinical xenograft model, MDA PCa 118b, also significantly suppressed tumor angiogenesis accompanied with decreased tumor growth in the bone. The results underscore the angiogenic role of FRS2α-mediated signaling in tumor epithelial cells in angiogenesis. They provide a rationale for treating PCa with inhibitors of FGF signaling. They also demonstrate the potential of overexpressed FRS2α as a biomarker for PCa diagnosis, prognosis and response to therapies.
INTRODUCTION
Tumor angiogenesis is required for tumor growth and progression by supplying nutrients and oxygen as well as removal of harmful metabolites and waste products. Without new blood vessels, tumors cannot normally expand beyond 1 mm 3 . 1 Microvessel density is considered a negative prognostic indicator for cancer. 2 Therefore, anti-angiogenesis is an alternative approach for cancer therapy rather than to a direct attack on tumor cells. 3, 4 However, anti-angiogenesis therapies are also accompanied by side effects and tumors eventually become resistant to the therapy. Detailed mechanistic studies are urgently needed to fully understand how tumors evade treatments and develop drug resistance. The fibroblast growth factor (FGF) was one of the first and remains a major angiogenic growth factor that have received extensive scrutiny. 5 Most of the mechanistic studies on the role of FGFs in angiogenesis have been focused on signaling in endothelial cells. How aberrant FGF signaling in the cancer cells contributes to angiogenesis of the tumor is still not clear.
The FGF family consists of 18 receptor-binding polypeptides that control a broad spectrum of cellular processes. FGFs exert their regulatory activities by activating FGF receptor (FGFR) tyrosine kinases encoded by four genes. 6 Both FGF and FGFR are expressed in a spatiotemporal-and cell type-specific pattern. They control embryonic development and maintain adult tissue homeostasis and function. Abnormal FGF signaling is often associated with cancer initiation and progression to malignancy. 6 FGFRs elicit signals by activating mitogen-activated protein kinase, phosphatidylinositol-3 kinase, PLC-γ and other pathways, either via FGF receptor substrate 2α (FRS2α) dependent or independent mechanisms. FRS2α is a broadly expressed membrane-bound adaptor protein that undergoes extensive tyrosine and serine/ threonine phosphorylation on FGFR activation. Disruption of Frs2α abrogates FGF-induced activation of mitogen-activated protein kinase and phosphatidylinositol-3 kinase. 7, 8 Prostate cancer (PCa) is the most commonly diagnosed cancer in American males. Extensive studies indicate that abnormal expression of the FGF or FGFR and aberrant activation of the FGF/FGFR signaling axis are associated with PCa development and progression. Amplification of the Fgfr1 gene frequently occurs in human PCa. 9 The acquisition of ectopic expression of FGFR1 in tumor epithelial cells where it is normally silent stands out as a remarkable change among FGFR isotypes. [10] [11] [12] [13] Forced expression of FGFR1 or multiple FGF ligands in prostate epithelial cells have been shown to induce prostate lesions in mouse models. [14] [15] [16] [17] [18] [19] [20] [21] [22] Ablation of Fgfr1 or Frs2α significantly reduces the development and progression of PCa induced by T antigens. 23, 24 FGF signaling promotes cell proliferation and reduces cell death. However, the full spectrum of how aberrant FGF signals contribute to PCa development and progression beyond driving high proliferative rate, and low cell mortality of cancer epithelial cells is still not fully understood.
Herein, we show that overexpression and elevated phosphorylation of FRS2α is associated with tumor angiogenesis as well as clinical features of human PCa. Ablation of Frs2α in prostate epithelial cells compromised angiogenesis in the TRAMP mouse prostate tumor model. Depleting FRS2α expression in human PCa cells also reduced their ability to recruit human umbilical cord endothelial cells (HUVEC) in vitro and host endothelial cells in vivo. A detailed analysis revealed that FRS2α-mediated signals in PCa cells contributed to tumor angiogenesis via promoting production of vascular endothelial growth factor A (VEGF-A) through HIF1α and cJUN pathways in the cells. This in turn recruited endothelial cells to the tumor. Thus, the results reveal a novel mechanism by which FRS2α-mediated signaling in PCa epithelial cells facilitates tumor angiogenesis within the microenvironment, unravel the potential of overexpressed FRS2α as a biomarker for PCa diagnosis and provide a rationale for treating PCa based on inhibiting FRS2α-mediated signaling in epithelial cells or pro-angiogenic factors controlled by it. PCa is associated with tumor  angiogenesis and poor prognosis of PCa patients  FGFR1 is overexpressed in~40% of human PCa  12,14 and forced  expression of ectopic FGFR1 in mouse prostate epithelial cells  increases tumor angiogenesis. 25 FGF9 promotes VEGF-A expression in LNCaP cells. 26 However, whether aberrant FGF signaling and its key mediator for downstream signaling FRS2α is associated with and contributes to overall tumor angiogenesis in human PCa has not been established. We assessed the clinical relevance of FRS2α expression and its correlation with microvessel density in human PCa by immunohistochemistry with anti-FRS2α and immunostaining with anti-CD31 antibodies. Both analyses were carried out on the same slides from the Massachusetts General Hospital (MGH) human prostate tissue microarrays (TMA) that comprised 225 PCa and 27 benign prostate samples (Figure 1a) . The samples were annotated with detailed patient follow-up information, including prostate-specific antigen (PSA) recurrence, Gleason Scores, pathological stages, patients' age and survival time. Although only a small group of cases had very strong staining (scores 7-9), the majority of the PCa samples had a score between 4 and 6. This was higher than the expression score in the adjacent non-cancerous tissues (Figure 1b ). In addition, elevated expression of FRS2α was found in PCa with high Gleason scores and in patients with high serum PSA (Figure 1c ). To determine whether FRS2α expression correlated with the prognosis of PCa patients, the association of FRS2α expression and PCa metastasis, PSA recurrence time and overall survival time of the 225 patients was analyzed (Figure 1c) . The data showed that the PSA recurrence-free survival and overall survival time of PCa patients were shorter in the groups exhibiting high FRS2α expression (score 43), compared with the group with low FRS2α expression (score ⩽ 3). Furthermore, appearance of metastases occurred faster in PCa, exhibiting high FRS2α than those with low FRS2α expression. In addition, expression levels of FRS2α positively correlated with microvessel density determined by CD31 staining (Pearson correlation: R = 0.55, P o 0.01).
RESULTS

Overexpression of Frs2α in human
To further implicate activity of FRS2α in angiogenesis in human PCa tissues, levels of activity of FRS2α were assessed by immunochemical staining of activate FRS2α (phosphorylated) in a separate PCa TMA. Expression of HIF1α, cJUN and CD31 were also assessed in the same array. This array included 99 primary PCa and 81 adjacent non-cancerous prostate tissue samples with the pathological features characterized by the vendor (Figure 1d) . The results showed that phosphorylation of FRS2α was higher in PCa than in benign tissues (2.23 ± 1.78 vs 1.68 ± 1.32, P o 0.02) and that the expression of cJUN was higher in tumors with Gleason Score ⩾ 7 than in those with Gleason Score ⩽ 7. In addition, the level of activities of FRS2α measured by its phosphorylation positively correlated with expression of cJUN (r = 0.358, P o 0.001), but not with HIF1α (r = 0.142, P = 0.164) and CD31 (r = 0.009, P = 0.312).
We then further evaluated the correlation coefficients between Frs2α expression and cJun, Hif1a and CD31 at the messenger RNA (mRNA) level in the Taylor data set GSE10645. 9 The results showed a positive correlation between Frs2α expression and cJun (r = 0.473, P o 0.001), Hif1a (r = 0.675, P o 0.001) and CD31 (r = 0.358, P o0.001) mRNA levels in the PCa tissues that comprise both epithelial and stromal cells. As microvessel density correlates with poor PCa progression, the data further demonstrate that overexpressed FRS2α in the tumor promotes PCa angiogenesis and suggest that FRS2α affects the clinical course of human PCa, as microvessel density correlates with poor PCa progression. Together, the data also suggest that the level of FRS2α expression in PCa tissues can serve as a biomarker for predicting outcomes of PCa patients.
Ablation of Frs2α reduces angiogenesis in PCa Ablation of Frs2α inhibits prostate tumor initiation, growth and progression in the TRAMP mouse prostate tumor model. 24 To investigate whether ablation of Frs2α suppressed PCa angiogenesis in the model, Frs2α was ablated specifically in prostate epithelial cells by crossing the floxed Frs2α (Frs2α Flox ) mice with the ARR2Pbi-Cre transgenic mice (hereafter designated as Frs2α CN for Frs2α conditional null). Prostate tumors were excised for examination from 5 month TRAMP mice. The Frs2α CN tumors had less CD31 + endothelial cells than control Frs2α Flox tumors. This suggests a reduction in vasculature of tumors deficient in Frs2α. To confirm this finding, immunostaining of the adjacent sections with additional microvasculature markers NG2 and lectin was carried out. Consistently, both NG2-and lectin-stained cells in Frs2α CN tumors were lower than those in Frs2α Flox tumors. In addition, expression of CD31, NG2 and VE-cadherin mRNA levels were lower in Frs2α CN tumors than those in control tumors ( Figure 2 ). Together, the results indicate that ablation of Frs2α results in reduced angiogenesis in the tumors.
Depletion of FRS2α expression in PCa cells compromises their ability to recruit endothelial cells via soluble factors As recruiting endothelial cells is a critical step in tumor angiogenesis, we then tested whether FRS2α was essential for PC3 human PCa cells to recruit endothelial cells via secretory factors. This was done by transfecting the cells with FRS2α-specific small interfering RNA (siRNA) to deplete FRS2α mRNA ( Figure 3A ).
The medium conditioned by the cells was collected and its activity for recruiting HUVECs was assessed by Transwell cell culture analyses ( Figure 3B ). The results showed that relative to the control cells, PC3 cells with reduced FRS2α in the bottom chamber had a reduced ability to promote migration of HUVECs in the upper chamber. Moreover, the medium conditioned by FRS2α-depleted PC3 cells also had reduced capacity to promote HUVEC cell migration in the scrape wound-healing assay ( Figure 3C ). The results indicate that FRS2α-mediated signals in PCa cells result in release of soluble factors that recruit endothelial cells. Endothelial cells can form luminal capillary-like structures in Matrigel in vitro. This characterizes an angiogenic switch that is stimulated by secretory factors from tumor cells. [27] [28] [29] We tested the activity of PC3 cell-conditioned medium for promoting endothelial cell tube formation. Again, the medium conditioned by FRS2α-depleted PC3 cells was also less active in inducing tube formation of HUVECs compared with that of control PC3 cells ( Figure 3D ). Notably, media conditioned by these two lines of PC3 cells did not affect HUVEC proliferation (data not shown).
We then determined whether the depletion of FRS2α expression in PCa cells also compromised their ability to induce endothelial migration and invasion in vivo. This was accomplished by depletion of FRS2α expression in PC3 cells by stable expression of FRS2α small hairpin RNA (shRNA) (Figure 4a ). The FRS2α-depleted PC3 cells were mixed with Matrigel, which were then 
Flox tumors, the expression of Vegf-a in Frs2α CN tumors was reduced (Figure 5a ). To investigate the mechanism underlying regulation of Vegf-a by FRS2α-mediated signals, quantitative reverse transcription -PCR analyses were used to assess the expression of potential Vegf-a upstream regulators. The expression of Sp1, Hif1a, Ap2 and cJun was reduced in Frs2α CN tumors at the mRNA level. Furthermore, immunostaining showed that expression of HIF1α and cJUN was downregulated at the protein level in Frs2α CN prostate and PCa (Figure 5b ). There were no changes in SP1 and AP2 expression in the Frs2α CN prostate (data not shown), possibly due to other redundant upstream regulators. Western analyses further confirmed that expression of cJUN and HIF1α were reduced at the protein level (Figure 5c ). The results suggest that downregulation of these two upstream regulators contribute to reduced expression of Vegf-a in Frs2α CN prostate and prostate tumors.
We also noted that depletion of FRS2α also compromised Vegfa, cJun and Hif1a expression in human PC3 cells, although the expression of Sp1 and Ap2 was not affected ( Figure 6A Figure 6B ). To further determine whether cJUN, HIF1α, SP1 and AP2-mediated FRS2α signals were required to support Vegf-a expression in PC3 cells, expression of these transcription factors was depleted with siRNA. Western blot analyses showed that expression of VEGF-A was reduced in the cells treated with cJun and Hif1a siRNA ( Figure 6C ). Consistently, overexpression of both HIF1α and cJUN in FRS2α-depleted PC3 cells partially restored their activity in promoting HUVEC migration ( Figure 6D ). Furthermore, chromatin immunoprecipitation (ChIP) assays revealed that capture of the Vegf-a promoter region by cJUN in pull-down assays was reduced in PC3 cells depleted of FRS2α ( Figure 6E , panels a and b). As HIF1α is unstable in the normoxic condition and thus it is difficult to do ChIP assays using cultured cells, similar ChIP experiments for HIF1α were carried out with Frs2α CN and control PCa tissues ( Figure 6E , panels c and d). The Vegf-a promoter sequence pulled down by HIF1α was reduced in Frs2α CN tumors compared with control tumors. The data demonstrate that HIF1α and cJUN are involved in the upregulation of VEGF-A expression by FRS2α-mediated signals in PCa cells.
We then assessed the role of FRS2α in human PCa in bone that is the most common site of lethal PCa metastasis. The expression of FRS2α was depleted in tumor cells isolated from MDA PCa 118b tumors, a preclinical human PCa xenograft model, by infection with adenovirus carrying shFrs2α (online Supplementary Figure  1a) . The cells were then implanted to the femurs of severe combined immunodeficiency mice for assessing their capacity for growth in bone. 17 FRS2α-depleted cells exhibited a lower tumorforming capacity in the mouse femurs than did control cells (online Supplementary Figures 1b and c) . This suggests that the FRS2α deficiency reduces growth of the tumor cells in bone. Moreover, the density of CD31 + endothelial cells was reduced in the FRS2α-depleted tumors (online Supplementary Figure 1d) , indicating that the angiogenesis in the tumor was compromised by depletion of FRS2α.
DISCUSSION
In this report, we demonstrated that hyperactivation of FRS2α-mediated angiogenic signaling was associated with tumor angiogenesis and poor clinical features of human PCa. This included high blood vessel density, high Gleason Score and high serum PSA. Furthermore, high FRS2α expression correlated with poor outcomes of PCa patients. These included high metastatic rates, shortened time to tumor recurrence and shorter survival times. We also showed that FRS2α underlies the previously established ability of FGF to elicit angiogenic signals. Ablation of Frs2α in prostate epithelial cells reduced VEGF-A expression by downregulating cJUN and HIF1α expression. This was accompanied through the inhibition of tumor angiogenesis and tumor growth in mouse PCa models. Depletion of FRS2α in human PCa cells also compromised the capability of the cells to recruit endothelial cells both in vivo and in vitro. Our results suggest that hyperactivation of the FRS2α-mediated angiogenic pathway can be used as biomarkers for PCa diagnosis and prognosis and particularly efficacy of treatments. They also suggest that suppressing FRS2α-mediated angiogenic signaling is promising for the development into a strategy for PCa treatment.
Fgfr1 is overexpressed in~40% of human PCa. 12, 14 Amplification of Frs2α and activation of the FGFR/FRS2α signaling pathway have been shown in liposarcomas. 30, 31 It has been previously reported that although no significant differences in Frs2α and Frs2β expression in small samples of human PCa were detected. However, double depletion of FRS2α and FRS2β in human PCa cells reduces cell proliferation, migration and invasion, as well as increase susceptibility to cytotoxic irradiation. 32 In this report, we report data derived from three sample pools that expression and activation of FRS2α were increased in human PCa at the protein level with the MGH PCa TMA, at the activity level with the commercial available PCa TMA, and at the mRNA level in the Taylor data set. The consistent conclusion derived from both TMA and the online data set indicates that neither ethnic factors nor detailed screening methods affected the conclusion that increased levels of FRS2α correlate with tumor angiogenesis in human PCa.
The levels of FRS2α phosphorylation in PCa, which indicated its activation, were higher than in adjacent non-cancerous tissues, although the statistical data showed that the difference was moderate. We found that the FRS2α phosphorylation levels in tissues adjacent to the tumor varied significantly. Some areas had a relatively high phosphorylated FRS2α, although others had low to undetectable phosphorylated FRS2α. It is possible that the phosphorylation of FRS2α in para-cancer tissues is affected by PCa adjacent to them. In resting adult mouse prostates, expression of FRS2α in luminal epithelial cells is below the detection limit of immunostaining. 24 Therefore, it is necessary to assess phosphorylated FRS2α in normal prostate tissues to determine whether phosphorylated FRS2α can be used as a biomarker for PCa diagnosis and prognosis. Nevertheless, the data here demonstrated that hyperactivation of FRS2α-mediated angiogenic signaling is associated not only with the malignance of prostate lesions, but also with poor prognosis for patients bearing PCa.
Furthermore, the results were consistent with the report that Fgfr1 is overexpressed in PCa and that overexpression of FGF9 increases VEGF-A expression in LNCaP cells and therefore predicts bone metastasis and poor prognosis of PCa. 17, 26 It has been shown that expression of ectopic FGFR1 in mouse prostate epithelial cells is oncogenic and that ectopic FGFR1 signaling promotes tumor angiogenesis. 25 In addition, expression of a constitutively active mutant of FGFR1 also increases Vegf1 expression and angiogenesis in hepatocellular carcinoma. 33 However, whether FRS2α is required for the angiogenic signals elicited by FGFR1 have not been reported. Our results not only confirm the tumor angiogenic roles of ectopic FGF signaling, but also unravel its underlying mechanism. This sheds new light on potential for development of new PCa treatments based on disruption of the FRS2α-mediated tumor angiogenic signaling axis.
The depletion of FRS2α in PCa cells reduced recruitment of endothelial cells to tumors via secreted factors. This suggests that FRS2α-mediated signals in tumor cells are involved in communication of tumor cells with host cells in the surrounding microenvironment. The results are consistent with our recent report that human PCa cells induce host bone cells to overexpress FGF2 and FGFR1, suggesting that the FGF axis mediates a synergistic interaction between PCa cells and bone cells in the tumor microenvironment to support metastatic PCa growth in bone. 34 As PCa cells overexpress FGFR1 that FGF2 is an activating ligand for FGFR1, the host cell FGF2 in turn will also enhances the angiogenic activity of PCa cells mediated by the FRS2α pathway. We further demonstrated here that depletion of FRS2α in MDA PCa 118b cells reduced tumorigenesis in the bone as well as reduced blood vessel density in the prostate tumors hosted by bone (online Supplementary Figure 1) . The results further indicated the importance of FRS2α-mediated signals in the crosstalk between PCa and host cells in the bone microenvironment.
The Vegf-a promoter region contains multiple consensus transcriptional regulatory factor-binding sites, which include SP1/SP3, AP1, AP2, Egr1, STAT3 and HIF1α. 35, 36 Although SP1 and AP2 can serve as downstream signaling molecules in the FGF pathway, overexpression of both AP2 and SP1 failed to restore the expression of VEGF-A in FRS2α-depleted PCa cells. This suggests that the two transcription factors are not sufficient to mediate angiogenic signals elicited by the FRS2α pathway. Moreover, ablation of Frs2α did not affect expression of the two transcription factors. The results suggest that regulators other than the FRS2α pathway that are upstream of VEGF-A may control VEGF-A expression via these transcription factors. Future efforts are needed to identify the upstream regulators for SP1 and AP2 involved in control of VEGF-A expression.
In summary, we report here that FRS2α-mediated signals contribute to PCa angiogenesis. The depletion of FRS2α expression suppressed PCa tumor angiogenesis and tumor growth. As FRS2α is a major mediator of the FGFR1 signaling complex at the intracellular membrane boundary, it likely accounts for the effects of hyperactive FGFR1 in tumors on tumor angiogenesis. Furthermore, hyperactivation of the FRS2α signaling pathway was associated with blood vessel density and pathological features of human PCa. The results suggest that suppression of the FRS2α-mediated pathway may be of therapeutic value for PCa therapies and that the hyperactive FRS2α signaling pathway is a potential biomarker for PCa diagnosis.
MATERIALS AND METHODS
Animals and isolation of tissues
All animals were housed in the Program of Animal Resources of the Institute of Biosciences and Technology, Texas A&M Health Science Center, and were handled in accordance with the principles and procedures of the Guide for the Care and Use of Laboratory Animals. All experimental procedures were approved by the Institutional Animal Care and Use Committee. Mice carrying the ARR2PBi-Cre transgenic, 37 Frs2α flox38 and TRAMP transgenic 39 alleles were maintained and genotyped as previously described. A total of 40 TRAMP mice were generated for this study. No randomization was used in this study.
Histological and immunostaining
Prostate or PCa tissues were fixed, dehydrated, embedded and sectioned according to standard procedures. 24 Antigens were retrieved by boiling in the citrate buffer (10 mM) for 20 min or as suggested by manufacturers. All sections were incubated with primary antibodies diluted in phosphatebuffered saline at 4°C overnight. The rabbit anti-cJUN ( For expression of Frs2α and CD31 in human PCa, the MGH PCa TMA was used. It includes 240 consecutive patients with PCa who underwent radical prostatectomy at the MGH from September 1993 to March 1995. 40 For analyses of phosphorylation of FRS2α in PCa, the human PCa TMA from the Shanghai Outdo Biotech Co, LTD (Shanghai, China, Cat No: HProAde180PG-01) was used. It includes 99 primary PCa and 81 adjacent non-cancerous prostate tissues with the pathological features characterized by the vendor. 41 Two experienced pathologists independently scored the results without any information about the samples. Only epithelial staining was counted. The scores were compared, and discrepant scores were subjected to re-examining by both individuals to achieve a consensus score. Immunostaining of PCa and stromal cells were evaluated separately. The percentage of positive cells was calculated and categorized as following: 0, 0%; 1, 1-10%; 2, 11-50%; 3, 50-75%; and 4, 75-100%. The staining intensity was visually scored and defined as 0, negative; 1, weak; 2, moderate; and 3, strong. /well) seeded in 24-well plates and were transfected with the indicated siRNAs. After being cultured in 37°C for 48 h, the cells were washed with phosphate-buffered saline and the culture media were replaced with 0.2% FBS Endothelial Growth Medium. Each well was then inserted a chamber with an 8.0 μm pore size membrane (BD Falcon, San Jose, CA, USA) containing 1x10 5 serum-starved HUVECs in 0.5 ml 0.2% FBSEarly Cleavage medium. After the co-culture for 32 h at 37°C, HUVEC cells were fixed with 4% paraformaldehyde and stained with hematoxylin. Three randomly picked areas in each insert were imaged and numbers of migrated HUVEC cells in each imaged area were counted. Data are mean ± s.d. of three replicates.
Scratch wound healing
HUVECs (1 × 10 5 cells/well) were seeded in six-well plates pre-coated with 0.1% gelatin. The cells were grown to confluence, followed by serumstarvation overnight and mitomycin treatment to stop cell proliferation. A scratch in each well was made with a pipette tip. The cells were then cultured in the Endothelial Growth Medium containing 0.5% FBS with or without supplemented with PC3-conditioned media. The number of HUVECs that migrated were counted using a phase-contrast microscope.
HUVEC tube formation
HUVECs (2x10 4 ) were seeded in 24-well plates containing 0.5 ml solidified Matrigel (10 mg/ml) and cultured in the Endothelial Growth Medium with or without the supplementation of PC3-conditioned medium for 8-12 h at 37°C. Images were acquired with a phase-contrast microscope. Average numbers of tubes were counted in three individual wells and presented as mean ± s.d.
Gene silencing with siRNA or shRNA siRNA targeting Frs2α, Hif1a, Ap2 and Sp1 were purchased from Dharmacon, GE health (Lafayette, CO, USA, Catalog number: L-006440-00-0005, J-026959-08-0002, J-006348-06-0002 and J-004018-08-0002. PC3 cells were transfected with siRNA 48 h before being used for functional assays. The coding sequences for shRNAs were cloned into the pLL3.7 plasmid for integrated into lentivirus. GIPZ lentiviral shRNA targeting Frs2α was obtained from Dharmacon, GE health. Stable cell lines containing Frs2 or non-silencing shRNAs were acquired by G418 selection.
Gene expression
Total RNA was extracted with the Ribopure RNA isolation reagent (Ambion, Austin, TX, USA). Reverse transcription was carried out with SuperScript III (Life Technologies, Grand Island, NY, USA) and random primers. Real-time PCR was performed on MX3000 (Stratagene, La Jolla, CA, USA), using the SYBR Green JumpStart Taq ReadyMix (Sigma, St Louis, MO, USA) with the primers list in Table 1 and following the manufacturer's protocol. The ratio between expression levels in the two samples was calculated by relative quantification, using β-actin as a reference transcript for normalization.
Western blot
Tumors or cultured cells were dissociated in 1% Triton X-100/ phosphatebuffered saline containing proteinase and phosphatase inhibitors. The lysates were separated on sodium dodecyl sulfate-polyacryl amide gel electrophoresis and blotted onto polyvinylidene fluoride membranes. The membranes were treated with 5% non-fat milk and incubated with primary antibodies overnight. Mouse anti-β-actin (1:2000) and rabbit anti-cJUN (1:10000) antibodies were from Cell Signaling Technology; rabbit anti-VEGF (1:200) and mouse anti-VEGF antibodies from Abcam; rabbit anti-HIF1α 
